

Alfonso E Bello

List of Publications by Citations

Source: <https://exaly.com/author-pdf/10375670/alfonso-e-bello-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

779
citations

9
h-index

13
g-index

13
ext. papers

875
ext. citations

3
avg, IF

3.36
L-index

#	Paper	IF	Citations
13	Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. <i>American Journal of Therapeutics</i> , 2001 , 8, 85-95	1	269
12	Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. <i>American Journal of Cardiology</i> , 2002 , 90, 959-63	3	264
11	Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. <i>American Journal of Gastroenterology</i> , 2012 , 107, 379-86	0.7	64
10	Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. <i>Journal of Rheumatology</i> , 2014 , 41, 2249-59	4.1	60
9	COX-2 specific inhibitors in the management of osteoarthritis of the knee: a placebo-controlled, randomized, double-blind study. <i>Journal of Clinical Rheumatology</i> , 2001 , 7, 151-9	1.1	35
8	Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. <i>Journal of Pain Research</i> , 2019 , 12, 975-995	2.9	28
7	Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. <i>Drug Safety</i> , 2014 , 37, 897-902	5.1	27
6	Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. <i>Postgraduate Medicine</i> , 2014 , 126, 82-91	3.7	10
5	DUEXIS(®) (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 327-39	3.8	9
4	Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons. <i>Physician and Sportsmedicine</i> , 2015 , 43, 193-9	2.4	5
3	One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. <i>Current Medical Research and Opinion</i> , 2015 , 31, 407-20	2.5	4
2	One-year open-label safety evaluation of the fixed combination of ibuprofen and famotidine with a prospective analysis of dyspepsia. <i>Current Medical Research and Opinion</i> , 2015 , 31, 397-405	2.5	2
1	Long Term Safety of an NSAID With Built-in Gastroprotection for Treatment of Pain and Inflammation Related to Oa and RA: Comparative Results From Blinded and Open Label One Year Safety Trials of a Single-Tablet Combination of Ibuprofen-Famotidine. <i>Gastroenterology</i> , 2011 , 140, S-585	13.3	2